Please provide your email address to receive an email when new articles are posted on . In patients with autoimmune pulmonary alveolar proteinosis, daily administration of inhaled molgramostim for 24 ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic ...

Please provide your email address to receive an email when new articles are posted on . Among patients with pulmonary alveolar proteinosis, treatment with daily inhaled recombinant human ...

Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of an abstract for ...

Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte–macrophage ...

In the first study of its kind, researchers have found that cholesterol-lowering statins may improve the conditions of people with a rare lung disease called autoimmune pulmonary alveolar proteinosis.

IN TODAY’S MEDICAL ALERT, THERE ARE 10,000 KNOWN RARE DISEASES. THEY IMPACT 30 MILLION PEOPLE IN THE US. FREDERICK COUNTY MAN IS ONE OF THEM. THESE SHARING HIS STORY OF SURVIVAL TO RAISE AWARENESS AND ...

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two ...

Poster Title: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from the IMPALA-2 Phase 3 Clinical Trial Session: English Poster Discussion “Rare ...